The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MPN 2026 | Insights into the mechanisms of disease progression in MPNs: from discovery science to the clinic
Stephen Oh, MD, PhD, Washington University School of Medicine, St. Louis, MO, provides insight into how his research exploring mechanisms of disease progression in MPNs has progressed from discovery to the clinic. Prof. Oh details how RSK1 and the DUSP6 pathway are critical in promoting disease progression and highlights an upcoming trial evaluating PMD-026 in patients with myelofibrosis. This interview took place at the ESH 11th Translational Research Conference on Myeloproliferative Neoplasms (ESH MPN 2026) in Estoril, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
